target/MAO/3

MAO-IN-3 (Compound 5), a reversible and competitive monoamine oxidase (MAO) inhibitor with inhibition constants (K i) of 0.6 μM for MAO A and 0.2 μM for MAO B, effectively suppresses LN-229 glioblastoma cell proliferation, as denoted by an inhibitory concentration (IC50) of 0.8 μM. This compound holds potential application in cancer research [1].

AChE/MAO-B-IN-3 is a dual inhibitor targeting both acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B), exhibiting inhibitory concentrations (IC50s) of 0.0257 μM and 0.0456 μM against human AChE and MAO-B, respectively. This compound holds potential for Alzheimer’s disease research.

MAO-B-IN-3 is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 96 nM and shows affinity for the 5-HT6 receptor with a Ki of 696 nM, making it suitable for Alzheimer's disease research [1].

Dual AChE-MAO B-IN-3 (Compound C10) is a potent inhibitor of both AChE and MAO-B, with IC50 values of 0.58 μM and 0.41 μM, respectively. It targets the catalytic anionic site and peripheral anionic site of AChE, making it relevant for Alzheimer’s disease (AD) research [1].

MAO-A B-IN-3 (Compound 12) demonstrated moderate permeability in in vitro experiments, with rates recorded at 16.49 nm s in Caco2 cells and 103.16 nm s in MDCK cells. The compound exhibited a high plasma protein binding rate of 90.97%, indicative of strong binding, suggesting it has an extended half-life and slow excretion characteristics.

AChE BChE MAO-B-IN-3, an indan-1-one derivative, is a potent inhibitor of human monoamine oxidase B (MAO-B) with an IC50 of 0.0359 μM and also demonstrates significant inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 0.0473 μM and 0.0782 μM, respectively. Exhibiting notable antioxidant activity, AChE BChE MAO-B-IN-3 holds considerable promise for Alzheimer's disease (AD) research.